“We are pleased with the progress we have made this quarter headlined by new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. This data, combined with the previously announced pharmacodynamic data from the study, underscores the potential of the RaniPill(R) to contribute to the GLP-1 receptor agonist space and the broader obesity therapeutics market,” said Talat Imran, Chief Executive Officer of Rani. “Additionally, we raised $20 million in aggregate gross proceeds from financings in July and October, enabling us to extend our cash runway into the third quarter of 2025. Looking ahead, we are excited to start our Phase 1 trial of RT-114 containing a GLP-1/GLP-2 dual agonist for the treatment of obesity next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics Holdings options imply 12.6% move in share price post-earnings
- Rani Therapeutics announces new preclinical PK data on GLP-1
- Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering
- 3 Penny Stocks to Watch Now, 10/15/24
- Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks